- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00955396
Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure
October 13, 2017 updated by: Biogen
A Randomized, Double-blind, Placebo-controlled Cross-over Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure
In this study the investigators will determine whether there is any effect of GSK1014802 on ambulatory blood pressure.
This will be a randomized, double-blind, placebo-controlled, repeat dose, 2 period cross-over study conducted in healthy male and female subjects.
Approximately 60 subjects will be randomised to receive GSK1014802 400 mg bid and placebo for 36 days with at least 1 week between treatment sessions.
A follow-up will occur 7-14 days after the last dose.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study, previously posted by GlaxoSmithKline (GSK), was transitioned to Convergence Pharmaceuticals, Ltd., which spun off from GSK. Convergence Pharmaceuticals, Ltd., has now been acquired by Biogen.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14202
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female between 18 and 65 years of age inclusive.
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests, liver function and cardiac monitoring.
- A female subject is eligible to participate if she is of:
Non-childbearing potential Child-bearing potential and agrees to use a contraception method.
- Male subjects must agree to use a contraception methods
- Body weight ≥ 50 kg and BMI within the range 19 - 40.0 kg/m2 (inclusive).
- Arm circumference ≥ 24 and ≤ 42 cm at mid level.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Exclusion Criteria:
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A positive pre-study drug screen.
- Alcohol levels above the legal limit for driving at screening and the detection of any alcohol within 24 h prior to the start of dosing in Treatment Periods 1 and 2.
- A positive test for HIV antibody.
- History of regular excessive alcohol consumption within 6 months of the study
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Use of prescription or non-prescription drugs, including any antihypertensive agent including diuretics, vitamins, herbal and dietary supplements
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period.
- Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
- Lactating females.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated.
- Subjects who work at night or whose work schedule includes rotating night time (10:00 PM to 6:00 AM) work.
- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
- Average daily caffeine intake equivalent to > 4 cups of coffee or > 6 cups of tea.
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
- Consumption of aged cheeses and meats, soy sauce and other tyramine rich sources within 1 day prior to the baseline assessments.
- Current or past history of symptomatic orthostatic hypotension or history of unexplained vasovagal episode(s).
- History of known or suspected seizures, including infantile febrile, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits).
- Any history of suicidal behaviour or suicidal ideation of type 4 or 5 on the C-SSRS within 3 months of the screening visit.
- History or currently diagnosed sleep apnea.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Period 1
|
Tablets
Tablets
Other Names:
|
Other: Period 2
|
Tablets
Tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in 24 h average SBP and DBP from Baseline to Day 36.
Time Frame: 36 days
|
36 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in 24 h average SBP and DBP from Baseline to Day 15. Change in average SBP and DBP within a dosing interval (12 h) from Baseline to Days 14 and 35.
Time Frame: 35 days
|
35 days
|
Change in 24 h average SBP and DBP from Baseline to Days 15 and 36 in subjects with baseline SBP 120-139 mmHg and also DBP 80-89 mmHg.
Time Frame: 36 days
|
36 days
|
Change in day-time outpatient (6:00 AM to 10:00 PM) SBP and DBP from Baseline to Days 15 and 36.
Time Frame: 36 days
|
36 days
|
Change in night-time outpatient (10:00 PM to 6:00 AM) SBP and DBP from Baseline to Days 15 and 36.
Time Frame: 36 days
|
36 days
|
Change in 24 h average ambulatory heart rate from Baseline to Days 15 and 36.
Time Frame: 36 days
|
36 days
|
Proportion of patients whose 24 h systolic and diastolic BP increased by < 5, 5-9, 1014, 15-19, and > 20 mm Hg compared to baseline.
Time Frame: 36 days
|
36 days
|
PK parameters of GSK1014802 following a single oral dose of GSK1014802 to healthy female subjects: Cmax, tmax, AUC (0-t) and, if possible, AUC(0-∞), λz and terminal phase half-life to healthy female subjects.
Time Frame: 1 day
|
1 day
|
PK parameters of GSK1014802 following repeated oral doses of GSK1014802 given twice daily to healthy male and female subjects: Cmax, tmax, AUC(0-12).
Time Frame: 36 days
|
36 days
|
PK/PD analyses to examine the correlation between ambulatory blood pressure and plasma levels and/or metrics of the systemic exposure (Cmax, AUC) of GSK1014802.
Time Frame: 36 days
|
36 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Biogen Medical Director, Biogen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 31, 2009
Primary Completion (Actual)
December 31, 2009
Study Completion (Actual)
December 31, 2009
Study Registration Dates
First Submitted
August 6, 2009
First Submitted That Met QC Criteria
August 6, 2009
First Posted (Estimate)
August 10, 2009
Study Record Updates
Last Update Posted (Actual)
October 16, 2017
Last Update Submitted That Met QC Criteria
October 13, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- 113210
- SCB113210
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer
-
BiogenRecruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
Angion Biomedica CorpQuotient SciencesNot yet recruitingHealthy VolunteerUnited States
-
University Hospital, ToursRecruitingNeurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults (PROSCEA)Healthy VolunteerFrance
-
BiogenActive, not recruiting
-
TeneoFour Inc.Novotech (Australia) Pty LimitedCompletedHealthy VolunteerAustralia
-
Spero TherapeuticsCompleted
-
AbbVieCompletedHealthy VolunteerUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States